Rakotomalala A, Escande A, Furlan A, Meignan S, Lartigau E. Hypoxia in solid tumors: how low oxygenation impacts the “Six Rs” of radiotherapy. Front Endocrinol. 2021;12:1084.
Google Scholar
Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L, Kolb HC. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal. 2014;21:1516–54.
Google Scholar
Hoskin PJ, Sibtain A, Daley FM, Wilson GD. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer. 2003;89:1290–7.
Google Scholar
Theodoropoulos VE, Lazaris AC, Sofras F, Gerzelis I, Tsoukala V, Ghikonti I, et al. Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol. 2004;46:200–8.
Google Scholar
Palit V, Phillips RM, Puri R, Shah T, Bibby MC. Expression of HIF-1alpha and Glut-1 in human bladder cancer. Oncol Rep. 2005;14:909–13.
Google Scholar
Eustace A, Irlam JJ, Taylor J, Denley H, Agrawal S, Choudhury A, et al. Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. Radiother Oncol J Eur Soc Ther Radio Oncol. 2013;108:40–47.
Google Scholar
Yang L, Taylor J, Eustace A, Irlam JJ, Denley H, Hoskin PJ, et al. A gene signature for selecting benefit from hypoxia modification of radiotherapy for high-risk bladder cancer patients. Clin Cancer Res. 2017;23:4761–8.
Google Scholar
Song YP, Mistry H, Irlam J, Valentine H, Yang L, Lane B, et al. Long-term outcomes of radical radiation therapy with hypoxia modification with biomarker discovery for stratification: 10-year update of the BCON (bladder carbogen nicotinamide) phase 3 randomized trial (ISRCTN45938399). Int J Radiat Oncol Biol Phys. 2021;110:1407–15.
Google Scholar
Bigos KJA, Quiles CG, Lunj S, Smith DJ, Krause M, Troost EGC, et al. Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours. Front Oncol. 2024;14:1331355.
Google Scholar
Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 2005;6:757–64.
Google Scholar
Lim AM, Rischin D, Fisher R, Cao H, Kwok K, Truong D, et al. Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Clin Cancer Res J Am Assoc Cancer Res. 2012;18:301–7.
Google Scholar
Rahman MA, Amirkhani A, Mempin M, Ahn SB, Deva AK, Baker MS, et al. The low-abundance plasma proteome reveals differentially abundant proteins associated with breast implant capsular contracture: a pilot study. Proteomes. 2024;12:22.
Google Scholar
Pietrowska M, Wlosowicz A, Gawin M, Widlak P. MS-based proteomic analysis of serum and plasma: problem of high abundant components and lights and shadows of albumin removal. Adv Exp Med Biol. 2019;1073:57–76.
Google Scholar
Rühle A, Wiedenmann N, Fennell JT, Mix M, Ruf J, Stoian R, et al. Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation-results from a prospective pilot trial. Eur J Nucl Med Mol Imaging. 2022;49:1650–60.
Google Scholar
Rühle A, Grosu AL, Wiedenmann N, Ruf J, Bieber B, Stoian R, et al. The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiation. Clin Transl Radiat Oncol. 2022;33:120.
Google Scholar
El-Benhawy SA, Sakr OA, Fahmy EI, Ali RA, Hussein MS, Nassar EM, et al. Assessment of serum hypoxia biomarkers pre- and post-radiotherapy in patients with brain tumors. J Mol Neurosci. 2022;72:2303–12.
Google Scholar
Yang L, West CM. Hypoxia gene expression signatures as predictive biomarkers for personalising radiotherapy. Br J Radio. 2018;92:20180036.
Google Scholar
Liu X, Abmanhal-Masarweh H, Iwanowytsch O, Okwelogu E, Arashvand K, Karabatsou K, et al. Plasma-to-tumour tissue integrated proteomics using nano-omics for biomarker discovery in glioblastoma. Nat Commun. 2025;16:3412.
Google Scholar
Hadjidemetriou M, Papafilippou L, Unwin RD, Rogan J, Clamp A, Kostarelos K. Nano-scavengers for blood biomarker discovery in ovarian carcinoma. Nano Today. 2020;34:100901.
Google Scholar
Hadjidemetriou M, Rivers-Auty J, Papafilippou L, Eales J, Kellett KAB, Hooper NM, et al. Nanoparticle-enabled enrichment of longitudinal blood proteomic fingerprints in Alzheimer’s disease. ACS Nano. 2021;15:7357–69.
Google Scholar
Hadjidemetriou M, Al-ahmady Z, Buggio M, Swift J, Kostarelos K. A novel scavenging tool for cancer biomarker discovery based on the blood-circulating nanoparticle protein corona. Biomaterials. 2019;188:118–29.
Google Scholar
Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M, et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol J Am Soc Clin Oncol. 2011;29:733–8.
Google Scholar
Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol J Am Soc Clin Oncol. 2010;28:4912–8.
Google Scholar
James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366:1477–88.
Google Scholar
Choudhury A, Porta N, Hall E, Song YP, Owen R, MacKay R, et al. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. Lancet Oncol. 2021;22:246–55.
Google Scholar
Smith TAD, West CML, Joseph N, Lane B, Irlam-Jones J, More E, et al. A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial. EBioMedicine. 2024;101:105032.
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540–556.e25.
Google Scholar
Bruijn, I de, Kundra, R, Mastrogiacomo, B, Tran, TN, Sikina, L, et al. Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 2023 https://doi.org/10.1158/0008-5472.CAN-23-0816.
Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, et al. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173:400–416.e11.
Google Scholar
Wang S, Liu X. The UCSCXenaTools R package: a toolkit for accessing genomics data from UCSC Xena platform, from cancer multi-omics to single-cell RNA-seq. J Open Source Softw. 2019;4:1627.
Google Scholar
Li Y, Dou Y, Da Veiga Leprevost F, Geffen Y, Calinawan AP, Aguet F, et al. Proteogenomic data and resources for pan-cancer analysis. Cancer Cell. 2023;41:1397–406.
Google Scholar
Lindgren CM, Adams DW, Kimball B, Boekweg H, Tayler S, Pugh SL, et al. Simplified and unified access to cancer proteogenomic data. J Proteome Res. 2021;20:1902–10.
Google Scholar
Szumilas M. Explaining odds ratios. J Can Acad Child Adolesc Psychiatry. 2010;19:227.
Google Scholar
Guerrero Quiles C, Fahy S, Bartak M, Gonzalez Abalos J, Powell E, Lodhi T, et al. Radiation-induced extracellular matrix remodelling drives prognosis and predicts radiotherapy response in muscle-invasive bladder cancer. Front Oncol. 2025;15:1616943.
Google Scholar
Miraglia E, Nylén F, Johansson K, Arnér E, Cebula M, Farmand S, et al. Entinostat up-regulates the CAMP gene encoding LL-37 via activation of STAT3 and HIF-1α transcription factors. Sci Rep. 2016;6:33274.
Google Scholar
Simko V, Iuliano F, Sevcikova A, Labudova M, Barathova M, Radvak P, et al. Hypoxia induces cancer-associated cAMP/PKA signalling through HIF-mediated transcriptional control of adenylyl cyclases VI and VII. Sci Rep. 2017;7:10121.
Google Scholar
Lucia K, Wu Y, Garcia JM, Barlier A, Buchfelder M, Saeger W, et al. Hypoxia and the hypoxia inducible factor 1α activate protein kinase A by repressing RII beta subunit transcription. Oncogene. 2020;39:3367–80.
Google Scholar
Taylor CT, Furuta GT, Synnestvedt K, Colgan SP. Phosphorylation-dependent targeting of cAMP response element binding protein to the ubiquitin/proteasome pathway in hypoxia. Proc Natl Acad Sci USA. 2000;97:12091–6.
Google Scholar
Shaikh D, Zhou Q, Chen T, Ibe JCF, Raj JU, Zhou G. cAMP-dependent protein kinase is essential for hypoxia-mediated epithelial–mesenchymal transition, migration, and invasion in lung cancer cells. Cell Signal. 2012;24:2396–406.
Google Scholar
Shabbir R, Quiles CG, Lane B, Zeef L, Hoskin PJ, Choudhury A, et al. Gene expression in muscle-invasive and non-muscle-invasive bladder cancer cells exposed to hypoxia. Cancers. 2025;17:2624.
Google Scholar
Comerford KM, Leonard MO, Karhausen J, Carey R, Colgan SP, Taylor CT. Small ubiquitin-related modifier-1 modification mediates resolution of CREB-dependent responses to hypoxia. Proc Natl Acad Sci. 2003;100:986–91.
Google Scholar
Jaśkiewicz M, Moszyńska A, Króliczewski J, Cabaj A, Bartoszewska S, Charzyńska A, et al. The transition from HIF-1 to HIF-2 during prolonged hypoxia results from reactivation of PHDs and HIF1A mRNA instability. Cell Mol Biol Lett. 2022;27:109.
Google Scholar
Gilkes DM, Wirtz D, Semenza GL. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2015;14:430–9.
Google Scholar
Quiles, CG, Gonzalez, AJ, Foussat, AS, Olympitis, A, Lodhi, T, Smith, V, et al. Hypoxia-induced extracellular matrix changes are conserved in cancer and directly impact radiotherapy benefit. bioRxiv 2025.04.04.647191 2025 https://doi.org/10.1101/2025.04.04.647191.
Zhang X-X, Luo J-H, Wu L-Q. FN1 overexpression is correlated with unfavorable prognosis and immune infiltrates in breast cancer. Front Genet. 2022;13:913659.
Google Scholar
Zhou W-H, Du W-D, Li Y-F, Al-Aroomi MA, Yan C, Wang Y, et al. The overexpression of fibronectin 1 promotes cancer progression and associated with M2 macrophages polarization in head and neck squamous cell carcinoma patients. Int J Gen Med. 2022;15:5027–42. Volume.
Google Scholar
Wang H, Zhang J, Li H, Yu H, Chen S, Liu S, et al. FN1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancers. Front Oncol. 2022;12:918719.
Google Scholar
Pan H, Luo Z, Lin F, Zhang J, Xiong T, Hong Y, et al. FN1, a reliable prognostic biomarker for thyroid cancer, is associated with tumor immunity and an unfavorable prognosis. Oncol Lett. 2024;28:510.
Google Scholar
Ji Z, Li X, Wang Y, Zhang X, Yang Z, Zhang Y, et al. Fibronectin 1 aggravates colon cancer metastasis by regulating RAP1B protein stability through Akt/CREB signalling pathway. J Cell Mol Med. 2025;29:e70702.
Google Scholar
Yokomizo A, Takakura M, Kanai Y, Sakuma T, Matsubara J, Honda K, et al. Use of quantitative shotgun proteomics to identify fibronectin 1 as a potential plasma biomarker for clear cell carcinoma of the kidney. Cancer Biomark. 2012;10:175–83.
Google Scholar
Ye G, Zhang X, Li M, Lin Z, Xu Y, Dong H, et al. Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer. BMC Cancer. 2023;23:412.
Google Scholar
Fu Z, Mowday AM, Smaill JB, Hermans IF, Patterson AV. Tumour hypoxia-mediated immunosuppression: mechanisms and therapeutic approaches to improve cancer immunotherapy. Cells. 2021;10:1006.
Wang B, Zhao Q, Zhang Y, Liu Z, Zheng Z, Liu S, et al. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. J Exp Clin Cancer Res. CR. 202;40:24.
Burrows N, Bashford-Rogers RJM, Bhute VJ, Peñalver A, Ferdinand JR, Stewart BJ, et al. Dynamic regulation of hypoxia-inducible factor-1α activity is essential for normal B cell development. Nat Immunol. 2020;21:1408–20.
Google Scholar
Abbott RK, Thayer M, Labuda J, Silva M, Philbrook P, Cain DW, et al. Germinal center hypoxia potentiates immunoglobulin class switch recombination. J Immunol. 2016;197:4014–20.
Google Scholar
Firmino NS, Cederberg RA, Lee CM, Shi R, Wadsworth BJ, Franks SE, et al. Germinal center hypoxia in tumor-draining lymph nodes negatively regulates tumor-induced humoral immune responses in mouse models of breast cancer. Oncoimmunology. 2021;10:1959978.
Cao R, Ma B, Wang G, Xiong Y, Tian Y, Yuan L. Characterization of hypoxia response patterns identified prognosis and immunotherapy response in bladder cancer. Mol Ther – Oncolytics. 2021;22:277–93.
Google Scholar
Smith V, Lee D, Reardon M, Shabbir R, Sahoo S, Hoskin P, et al. Hypoxia is associated with increased immune infiltrates and both anti-tumour and immune suppressive signalling in muscle-invasive bladder cancer. Int J Mol Sci. 2023;24.
Georgila K, Vyrla D, Drakos E. Apolipoprotein A-I (ApoA-I), immunity, inflammation and cancer. Cancers. 2019;11.
Galmiche A, Saidak Z, Ghiringhelli F. Targeting coagulation to unlock antitumor immunity? Oncoimmunology. 2022;11.
Ward MP, Kane LE, Norris LA, Mohamed BM, Kelly T, Bates M, et al. Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell? Mol Cancer. 2021;20:59.
Tang S, Lai KN, Chan TM, Lan HY, Ho SK, Sacks SH. Transferrin but not albumin mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells. Am J Kidney Dis J Natl Kidney Found. 2001;37:94–103.
Google Scholar
Martino MD, Daviaud C, Vanpouille-Box C. Radiotherapy: an immune response modifier for immuno-oncology. Semin Immunol. 2021;52.
Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004;5:429–41.
Google Scholar
Kallman RF, Dorie MJ. Tumor oxygenation and reoxygenation during radiation theraphy: their importance in predicting tumor response. Int J Radiat Oncol Biol Phys. 1986;12:681–5.
Google Scholar
Simon NI, Kydd AR, Akbulut D, Takeda D, Del Rivero J, Merino M, et al. Small cell carcinoma of the bladder: review of pathogenesis, presentation, and management. Bladder Cancer. 2025;11:23523735251370956.
Google Scholar
Atasoy BM, Dane F, Alsan Cetin I, Ozgen Z, Ucuncu Kefeli A, Ibrahimov R, et al. Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients. Clin Transl Oncol. 2014;16:91–95.
Google Scholar
Miyake M, Iemura Y, Oda Y, Miyamoto T, Nishimura N, Haramoto M, et al. Bladder preservation with concurrent chemoradiotherapy for muscle-invasive bladder cancer: Retrospective comparison of three regimens. Bladder. 2024;11:e21200009.
Google Scholar
Nemati M, Hsu C-Y, Nathiya D, Kumar MR, Oghenemaro EF, Kariem M, et al. Gemcitabine: immunomodulatory or immunosuppressive role in the tumor microenvironment. Front Immunol. 2025;16:1536428.
Google Scholar
Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70:3052–61.
Google Scholar
Toren P, Wilkins A, Patel K, Burley A, Gris T, Kockelbergh R, et al. The sex gap in bladder cancer survival — a missing link in bladder cancer care? Nat Rev Urol. 2024;21:181–92.
Google Scholar
Kaneko S, Li X. X chromosome protects against bladder cancer in females via a KDM6A -dependent epigenetic mechanism. Sci Adv. 2018;4:eaar5598.
Google Scholar
Wang Y, Bhandary P, Moore JH, Li X, Wang Z. Integrative microRNA and transcriptome analysis reveals sex-specific molecular divergence in human bladder cancer. Biol Sex Differ. 2026;17:29.
Google Scholar
Abumanhal-Masarweh H, Assi SA, Liu X, Guerrero Quiles C, Lodhi T, Williams KJ, et al. Longitudinal plasma nano-proteomics reveals acute systemic responses to radiotherapy and predictive biomarkers of late toxicity. Commun Med. 2026 https://doi.org/10.1038/s43856-026-01552-3.
